Translating novel science into life-saving medicines
Targeting those patients most
likely to benefit
Developing precision medicines for cancer
Skip to content
Board of Directors
Tipifarnib – HRAS
Tipifarnib – PTCL
Tipifarnib – MDS
KO-947 (ERK Inhibitor)
KO-539 (Menin-MLL Inhibitor)
Events & Presentations
Kura Oncology to Participate in Three Upcoming Investor Conferences»
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia»
Kura's pipeline consists of small molecule drug candidates designed to inhibit mutated or abnormally functioning signaling pathways that drive cancer growth.
Kura is conducting clinical trials intended to identify and enroll patients most likely to respond to treatment.